A phase II, double-blind, randomised, controlled, dose ranging study to evaluate the safety, immunogenicity, dose response and schedule response of a meningococcal A conjugate vaccine administered concomitantly with local expanded program on immunisation (EPI) vaccines in healthy infants

Trial Profile

A phase II, double-blind, randomised, controlled, dose ranging study to evaluate the safety, immunogenicity, dose response and schedule response of a meningococcal A conjugate vaccine administered concomitantly with local expanded program on immunisation (EPI) vaccines in healthy infants

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Meningococcal vaccine group A conjugate (Primary) ; Hib-DTP-hepatitis B vaccine; Measles virus vaccine live; Poliovirus vaccine inactivated; Yellow fever vaccine
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Measles; Meningococcal group A infections; Pertussis; Poliomyelitis; Tetanus; Yellow fever
  • Focus Pharmacodynamics
  • Sponsors Serum Institute of India
  • Most Recent Events

    • 29 Oct 2015 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 21 Sep 2015 Planned End Date changed from 31 Dec 2012 to 31 Dec 2017 as reported by ISRCTN: Current Controlled Trials.
    • 21 Sep 2015 Status changed from completed to recruiting as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top